Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment

Hepatocellular carcinoma

(2021) Josep M. Llovet et al.   Nature Reviews Disease Primers

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

(2021) Josep M. Llovet et al.   Nature Reviews Gastroenterology & Hepatology

Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference

(2020) Josep M. Llovet et al.   HEPATOLOGY

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study

(2019) Qiuhe Wang et al.   JOURNAL OF HEPATOLOGY

Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis

(2019) Huayu Yang et al.   Frontiers in Oncology

Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach

(2019) Guohong Han et al.   HEPATOLOGY

Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

(2018) Jorge A. Marrero et al.   HEPATOLOGY

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2018) Peter R. Galle et al.   JOURNAL OF HEPATOLOGY

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models

(2018) Masahiro Matsuki et al.   Cancer Medicine

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden—Reply

(2017) Christina Fitzmaurice et al.   JAMA Oncology

Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data

(2016) Riccardo Lencioni et al.   HEPATOLOGY

Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

(2015) Philip J. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma

(2012) Seiki Miura et al.   BMC CANCER

Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis

(2010) Christine Gauglhofer et al.   HEPATOLOGY

PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients

(2010) Feng Shi et al.   INTERNATIONAL JOURNAL OF CANCER

Immune Regulation of Cancer

(2010) Mary L. Disis   JOURNAL OF CLINICAL ONCOLOGY

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

(2009) Q. Gao et al.   CLINICAL CANCER RESEARCH